Key facts
- Biosceptre’s last known valuation is $431.9M (Feb 2024).
- It has raised $52.8M; the latest was Later Stage VC ($10.9M) in Oct 2025.
- Notable investors include Innovate UK, Norcliffe Capital, Jungle Capital, McKenny-McFarlane Capital, Tuspark Science and Technology Service Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Biosceptre
- ·The full record, as it builds
Funding rounds
No funding rounds for Biosceptre are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biosceptre
Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer. The company's therapeutics develop next-generation cancer treatments targeting viruses via a range of modalities, including systemic antibodies, vaccines, and topical therapeutics, and clinical programs include systemic antibody-based therapeutics and vaccines, enabling patients to get accurate cancer treatment remedies.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2004
- Employees
- 16
- Website
- biosceptre.com/
- Ownership
- Privately Held (backing)
Biosceptre doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biosceptre shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biosceptre in its N-PORT filings yet. We sweep new filings monthly.